News

BVBiomedical Ltd is pleased to announce that it has been selected by Business Magazine as one of the top 100 life science companies in 2024.

PRESS: BVBiomedical, is pleased announce the development of a breakthrough treatment for neurodegenerative conditions. These include motor neurone disease, multiple sclerosis, concussion/CTE and post traumatic stress disorder. All of which share some common pathologies. The treatment is based on a naturally occurring hormone, relaxin. It has been proven to be safe and effective. Enhanced forms of this hormone have been created by Johnson & Johnson, Sanofi, AstraZenica and Tectonic Therapeutics to treat heart and kidney disease. BVBiomedical has initiated discussions with these companies to co-develop their enhanced relaxin molecules in neurodegeneration. These forms are ready to begin phase 2 clinical trials to treat these diseases. For more information or to partner with BVBiomedical contact: Roy Garvin, PhD, Chief Science Officer at garvin@bvbiomed.com, or on 07518795083.

BVBiomedical Ltd were invited to present to the executive board of UK TBI-Reporter on the use of relaxin in the treatment of concussion and TBI.

BVBiomedical Ltd was invited to the Department of Health and Social Care to attend a round table discussion on the prevention and treatment of concussion in sport.

BVBiomedical Ltd entered into a collaboration with Innovate UK Business Growth, The national innovation & growth service for ambitious businesses (https://iuk.ktn-uk.org/business-growth/).

Australian Patent No. 2016320544 in the name of BVBiomedical Limited For a Novel Therapy was granted.

United States Patent No. 11344607 in the name of BVBiomedical Limited For a Novel Therapy was granted.

BVBiomedical Ltd entered into a collaboration with Cognition Health, London to develop a clinical trial protocol for the use of relaxin to treat CTE in retired rugby players.